Silico Research home page
Silico Research is a leader in the emerging field of the study of alliances, partnerships and intellectual property in intellectually-driven industries and economic sectors including the life sciences, technology and public sector research. What sets Silico Research apart is the evidence-based nature of our analysis and our deep databases spanning multiple sectors and regions. The following are the highlights of a few pieces of research that we have undertaken recently:
BioPartnering 2008
The terms of a deal on offer, a partner's development expertise and their alliance management skills are the top drivers of alliance formation according to senior partnering business development executives in the pharmaceutical, biotechnology and medical devices industry and research institutes who participated in the BioPartnering 2008 survey.
Alliances drive the hunt for clean energy
Motor companies looking to perfect hybrid and plug-in electric cars as the solution to soaring oil costs and concerns about the environment see alliances as the way forward.
Funding research and development through spin-outs
In a bid to cut costs AstraZeneca is spinning out its efforts to find new drugs for gastrointestinal (GI) disorders to a new company called Albireo. Part of the decision reflects AztraZeneca's recent problems with its drug, Nexium, an ulcer treatment, which has been declining in profit and its decision to direct its energies on respiratory, cancer and infectious diseases.
The impact of large alliances on share prices
Do alliances and partnerships really detract from the market value of biotechnology companies?
Reducing alliance risks
Consultants are in business to disagree with each other. Which makes it odd is that they all agree on at least one thing, somewhere around a half of all alliances 'fail'. But are they right? Research by Silico and IBM conducted among 148 senior executives in the biopharmaceutical industry indicates that far fewer of the partnerships which analysts reported as having failed can be regarded as true failures.
Pfizer invests in web-based software company
Why is Pfizer so heavily behind a struggling web-based software company operating in a crowded space?
Life science companies optimistic about 2008
A recent survey by Silico Research has revealed that executives in life science companies are optimistic about the prospects for their industry going into 2008.
|| 
